Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Key Points

• Insider sale: Anne Lesage sold 30,000 Pharvaris shares at an average price of $38.30, generating $1.149 million. Her remaining stake fell to 56,450 shares, a 34.7% reduction.
• Stock performance and outlook: Pharvaris shares rose 3.7% to $39.44, while analysts maintained a generally positive view with a consensus “Moderate Buy” rating and a $59.50 price target.
• Investor and business activity: Several institutional investors increased their positions, even as Pharvaris reported a quarterly EPS loss of $0.81 versus the expected $0.75 loss. The company is developing oral deucrictibant therapies for hereditary angioedema.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Anne Lesage sold 30,000 shares of the business's stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $38.30, for a total transaction of $1,149,000.00. Following the completion of the transaction, the insider owned 56,450 shares in the company, valued at approximately $2,162,035. The trade was a 34.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Anne Lesage also recently made the following trade(s):

• On Tuesday, June 30th, Anne Lesage sold 30,703 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47.
• On Tuesday, June 30th, Anne Lesage sold 27,872 shares of Pharvaris stock. The stock was sold at an average price of $35.48, for a total value of $988,898.56.
• On Monday, June 29th, Anne Lesage sold 6,997 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total transaction of $245,244.85.
• On Monday, June 29th, Anne Lesage sold 10,600 shares of Pharvaris stock. The shares were sold at an average price of $35.07, for a total transaction of $371,742.00.

Pharvaris Stock Up 3.7%

PHVS traded up $1.42 during trading on Monday, reaching $39.44. 472,347 shares of the company were exchanged, compared to its average volume of 392,807. The company has a market cap of $2.58 billion, a price-to-earnings ratio of -12.98 and a beta of -2.33. Pharvaris N.V. has a 12-month low of $20.65 and a 12-month high of $43.25. The company's 50-day moving average is $35.09 and its two-hundred day moving average is $31.41.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities analysts forecast that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

A number of large investors have recently made changes to their positions in the business. venBio Partners LLC bought a new stake in Pharvaris in the second quarter valued at $160,569,809. Deerfield Management Company L.P. lifted its position in shares of Pharvaris by 21.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company's stock worth $60,939,000 after purchasing an additional 425,000 shares during the period. Wellington Management Group LLP boosted its stake in shares of Pharvaris by 12.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company's stock valued at $82,748,000 after purchasing an additional 274,034 shares in the last quarter. Commodore Capital LP boosted its stake in shares of Pharvaris by 1.6% during the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company's stock valued at $54,211,000 after purchasing an additional 29,525 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP increased its position in shares of Pharvaris by 72.7% during the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company's stock valued at $45,796,000 after buying an additional 772,583 shares during the period.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PHVS. Citigroup reaffirmed a "market outperform" rating on shares of Pharvaris in a research note on Wednesday, September 9th. Rosenblatt Securities set a $60.00 price target on shares of Pharvaris in a research note on Wednesday, September 9th. Royal Bank Of Canada raised their price objective on Pharvaris from $52.00 to $62.00 and gave the company an "outperform" rating in a research note on Wednesday, September 9th. Wedbush lifted their price objective on Pharvaris from $42.00 to $50.00 and gave the stock an "outperform" rating in a report on Wednesday. Finally, Morgan Stanley boosted their target price on Pharvaris from $46.00 to $62.00 and gave the company an "overweight" rating in a research note on Wednesday, September 9th. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $59.50.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.